MA41123A - Polythérapie pour le traitement du cancer - Google Patents

Polythérapie pour le traitement du cancer

Info

Publication number
MA41123A
MA41123A MA041123A MA41123A MA41123A MA 41123 A MA41123 A MA 41123A MA 041123 A MA041123 A MA 041123A MA 41123 A MA41123 A MA 41123A MA 41123 A MA41123 A MA 41123A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer treatment
cancer
treatment
Prior art date
Application number
MA041123A
Other languages
English (en)
Inventor
Austin Gurney
Timothy Charles Hoey
Wan-Ching Yen
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MA41123A publication Critical patent/MA41123A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
MA041123A 2014-12-02 2015-12-01 Polythérapie pour le traitement du cancer MA41123A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086435P 2014-12-02 2014-12-02
US201562210545P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
MA41123A true MA41123A (fr) 2017-10-10

Family

ID=56092663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041123A MA41123A (fr) 2014-12-02 2015-12-01 Polythérapie pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20170266276A1 (fr)
EP (1) EP3226901A4 (fr)
JP (1) JP2018502833A (fr)
CN (1) CN107708731A (fr)
AU (1) AU2015358506A1 (fr)
CA (1) CA2969401A1 (fr)
MA (1) MA41123A (fr)
MX (1) MX2017006938A (fr)
WO (1) WO2016090024A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
WO2015130172A1 (fr) 2014-02-28 2015-09-03 Merus B.V. Anticorps qui se lient à l'egfr et à l'erbb3
CA2961374A1 (fr) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
CN108602888B (zh) 2015-10-23 2022-10-04 美勒斯公司 抑制癌症生长的结合分子
CN109789206A (zh) 2016-09-16 2019-05-21 生态有限公司 抗体和检查点抑制剂的组合疗法
AU2018246873B2 (en) 2017-03-31 2021-05-06 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
SG11202001050PA (en) 2017-08-09 2020-03-30 Merus Nv Antibodies that bind egfr and cmet
AU2018378668A1 (en) * 2017-12-07 2020-06-25 National Health Research Institutes Anti-RSPO3 antibodies
CA3179862A1 (fr) * 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Edition de base de angptl3 et procedes d'utilisation de celle-ci pour le traitement d'une maladie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10257252A1 (de) * 2002-12-07 2004-08-12 Deere & Company, Moline Presse, insbesondere Rundballenpresse
US8158757B2 (en) * 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
CN106167526A (zh) * 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
MX2015000565A (es) * 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
US9713612B2 (en) * 2013-03-12 2017-07-25 Curegenix, Inc. Compounds for treatment of cancer

Also Published As

Publication number Publication date
JP2018502833A (ja) 2018-02-01
WO2016090024A4 (fr) 2016-09-22
WO2016090024A3 (fr) 2016-08-04
WO2016090024A2 (fr) 2016-06-09
US20170266276A1 (en) 2017-09-21
AU2015358506A1 (en) 2017-06-08
EP3226901A4 (fr) 2018-08-08
EP3226901A2 (fr) 2017-10-11
CA2969401A1 (fr) 2016-06-09
CN107708731A (zh) 2018-02-16
MX2017006938A (es) 2017-08-24

Similar Documents

Publication Publication Date Title
NL301117I2 (nl) trastuzumab deruxtecan
MA45429A (fr) Polythérapie pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA41858A (fr) Polythérapie fgfr/pd-1 destinée au traitement du cancer
MA41555A (fr) Polythérapie pour le traitement du cancer
MA41123A (fr) Polythérapie pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA42459A (fr) Nouvelle approche pour le traitement du cancer par immunomodulation
DK3119808T3 (da) Antistofsammensætninger til tumorbehandling
MA43000A (fr) Polythérapie pour le traitement de tumeurs malignes
DK3560954T3 (da) Modificeret j-kæde
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA42999A (fr) Polythérapie pour le traitement de malignités
DK3341479T3 (da) LNA-G-Proces
MA47408A (fr) Traitement du cancer
MA45780A (fr) Méthodes de traitement du cancer de la prostate
FR3031056B1 (fr) Enceinte pour le formage electro-hydraulique
MA47474A (fr) Polythérapie rationelle pour le traitement du cancer
DK3407909T3 (da) Cancerbehandling
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
MA51688A (fr) Protéines prohémostatiques pour le traitement de saignement
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives